It definitely appears that they had some initial technology which looked promising but has failed to mature into a viable replacement for commercially available tests.<p>What I&#x27;m wondering is how well Theranos&#x27; investors did their due dilligence. It&#x27;s not completely incredible that a VC might fund a company based on its team and market position even if its core technology isn&#x27;t a viable product of a long-term business, but it would be somewhat surprising.